Carisma Therapeutics (NASDAQ:CARM) Insider Michael Klichinsky Sells 119,347 Shares

Carisma Therapeutics Inc. (NASDAQ:CARM) insider Michael Klichinsky sold 119,347 shares of the stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $0.26, for a total transaction of $31,030.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Michael Klichinsky also recently made the following trade(s):

• On Thursday, October 2nd, Michael Klichinsky sold 200,000 shares of Carisma Therapeutics stock. The stock was sold at an average price of $0.25, for a total transaction of $50,000.00.
• On Wednesday, October 1st, Michael Klichinsky sold 165,000 shares of Carisma Therapeutics stock. The stock was sold at an average price of $0.26, for a total transaction of $42,900.00.

Carisma Therapeutics Stock Down 3.4%

NASDAQ CARM opened at $0.26 on Friday. The stock’s 50-day simple moving average is $0.30 and its two-hundred day simple moving average is $0.30. Carisma Therapeutics Inc. has a twelve month low of $0.14 and a twelve month high of $1.27. The company has a market capitalization of $10.90 million, a price-to-earnings ratio of -0.17 and a beta of 2.06.

Analyst Ratings Changes

Several analysts have issued reports on CARM shares. D. Boral Capital reaffirmed a “buy” rating and issued a $1.00 target price on shares of Carisma Therapeutics in a research note on Friday, August 8th. Evercore ISI raised shares of Carisma Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 15th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Carisma Therapeutics in a research report on Saturday, September 27th. Two research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $1.93.

Institutional Trading of Carisma Therapeutics

An institutional investor recently bought a new position in Carisma Therapeutics stock. Jane Street Group LLC bought a new position in shares of Carisma Therapeutics Inc. (NASDAQ:CARM) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 150,810 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned 0.36% of Carisma Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 44.27% of the company’s stock.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.